Safety and efficacy of injectable and oral maropitant, a selective neurokinin1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 31, Issue 6, 2008, Pages 538-543

  Ramsey, D S ^a   Kincaid, K ^a   Watkins, J A ^a   Boucher, J F ^a   Conder, G A ^a   Eagleson, J S ^a   Clemence, R G ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERENIA; MAROPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; TABLET; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; DOGS; DRUG TOXICITY; FEMALE; INJECTIONS, SUBCUTANEOUS; MALE; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; VOMITING;

CANIS FAMILIARIS;

EID: 55949106702     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2008.00992.x     Document Type: Article

References (11)

1. Benchaoui, H.A., Cox, S.R., Schneider, R.P., Boucher, J.F. Clemence, R.G. (2007a) The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. Journal of Veterinary Pharmacology and Therapeutics, 30, 336 344.
2. Benchaoui, H.A., Siedek, E.M., De La Puente-Redondo, V.A., Tilt, N., Rowan, T.G. Clemence, R.G. (2007b) Confirmation of the efficacy of maropitant for the prevention of emesis associated with motion sickness in dogs presenting as clinical patients. Veterinary Record, 161, 444 447.
3. Conder, G.A., Sedlacek, H.S., Boucher, J.F. Clemence, R.G. (2008). Efficacy and safety of maropitant, a selective neurokinin-1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs. Journal of Veterinary Pharmacology and Therapeutics, Submitted.
4. TM) in the treatment of ongoing emesis caused by a variety of underlying clinical aetiologies in canine patients in Europe. Journal of Small Animal Practice, 48, 93 98.
5. 1 receptor anragonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. British Journal of Anaesthesia, 82, 274 276.
6. 1 receptor antagonist GR203040. British Journal of Pharmacology, 116, 3158 3163.
7. 1 receptor, and potent broad-spectrum anti-emetic activity. Regulatory Peptides, 65, 45 53.
8. Sedlacek, H.S., Ramsey, D.S., Boucher, J.F., Eagleson, J.S., Conder, G.A. Clemence, R.G. (2008). Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. Journal of Veterinary Pharmacology and Therapeutics, Submitted.
9. Vail, D.M., Rodabaugh, H.S., Conder, G.A., Boucher, J.F. Mathur, S. (2007) Efficacy of injectable maropitant (Cerenia™) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients. Veterinary and Comparative Oncology, 5, 38 46.
10. VICH GL9 (2001) Good Clinical Practice. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products. FDA Guidance for Industry 85, pp. 29.
11. 1 receptor. British Journal of Pharmacology, 115, 84 94.